Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- J Int Med Res1
Search Results
Sort by
- BookPaulo Roberto Barbosa Evora, Andrea Carla Celotto, Agnes Afrodite Sumarelli Albuquerque, Patricia Martinez Évora.Summary: This unique work presents one of the most significant organ failure condition--cardiocirculatory shock--and the prominent role of Methylene Blue (MB). Through their extensive experience, the authors consider that the lifesaving feature of MB is still underestimated. For this reason they outline key concepts of MB, mentioning essential experimental data, yet focusing mainly on its application in the care of critically ill patients. In an easy-to-read format, the 18 chapters were organized in a didactically structured order, distributed in four parts. The first part introduces the general conceptual aspects and physiology of the endothelium. The second part presents the particularities of endothelial dysfunction in different types of shock. Methylene blue is discussed in detail in the third part. In the fourth part, particular situations of endothelial dysfunction, such as heart surgery and organ transplantation, are described. Additionally, the two complementary subjects of acid-base balance and the therapeutic use of inhaled nitric oxide are mentioned. Finally, looking for therapeutic alternatives for what we classify as "vasoplegic endothelial dysfunction", MB remains promising as an adjuvant to sympathomimetic amines. The combination of three recently proposed concepts may be useful in obtaining better results against the high mortality rates in critically ill patients. These three concepts are "wide-spectrum vasopressors", vasopressor economy strategies, and microcirculation protection against the harmful effects of using high concentrations of amines. This book's translational approach will appeal to a variety of readers within the health specialties of medicine, biomedicine, physiotherapy, nursing, odontology, and basic science.
Contents:
Part I - General Conceptual Aspects
Introduction
Physiology of the Endothelium
PART 2 PARTICULARITIES OF ENDOTHELIAL DYSFUNCTION IN DIFFERENT TYPES OF SHOCK
Circulatory Shock: A Conceptual and Practical Approach
Circulatory Shock, Ischemia Reperfusion Injury, Inflammatory Response Syndrome (SIRS) and Multiple Organ Failure
Endothelial Dysfunction in Hemorrhagic Shock
Endothelial Dysfunction in Cardiogenic Shock
Endothelial Dysfunction in Distributive Shock
PART 3 METHYLENE BLUE
Methylene blue
The Inhibition of Guanylate Cyclase by Methylene Blue as Therapeutic Proposal for Vasoplegia Associated with Shock
Methylene Blue in the Treatment of Anaphylaxis
Methylene Blue in Children and Neonates
Methylene Blue and Burns
Cardiac arrest and neuroprotection by methylene blue
Methylene Blue and Endocarditis
PART 4 ENDOTHELIAL DYSFUNCTION IN SPECIFIC SITUATIONS
Vasoplegic syndrome in heart surgery
Vasoplegic Endothelial Dysfunction In Orthotopic Liver Transplantation
Acid-base Balance
The therapeutic use of inhaled nitric oxide. - ArticleTrujillo H, Manotas R, Ramirez JI, Uribe A, Agudelo N, Zapata CT, Zuluaga AI, de Vidal EL.J Int Med Res. 1978;6(4):257-65.Amikacin was used in the treatment of various Gram-negative infections in sixty-six children ranging in age from two days to thirteen years. Over 72% of the infections treated were classified as severe and the remainder were moderate. Among infections in which the site of origin was the urinary or gastro-intestinal tract, amikacin achieved thirty-eight (95%) complete or partial cures in forty patients. In respiratory tract infections, amikacin completely or partially cured six (75%) out of eight patients. The remaining eighteen infections involved skin, soft tissue and other miscellaneous categories in which amikacin therapy resulted in seventeen (94%) complete or partial cures. Overall, amikacin achieved fifty-four complete cures and seven clinical or bacteriological cures in sixty-six patients, which represents an 82% complete cure rate and 10% partial cure rate for all the patients in the study.